as 05-20-2024 9:37am EST
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Founded: | N/A | Country: | France |
Employees: | N/A | City: | N/A |
Market Cap: | 122.0B | IPO Year: | N/A |
Target Price: | $55.00 | AVG Volume (30 days): | 2.0M |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | 4.19% | Dividend Payout Frequency: | Annual |
EPS: | 2.34 | EPS Growth: | -13.13 |
52 Week Low/High: | $42.63 - $55.72 | Next Earning Date: | 04-25-2024 |
Revenue: | $51,604,444,444 | Revenue Growth: | 18.56% |
Revenue Growth (this year): | 2.3% | Revenue Growth (next year): | 7.05% |
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
Motley Fool
2 days ago
Zacks
3 days ago
Motley Fool
3 days ago
Zacks
4 days ago
Benzinga
4 days ago
Motley Fool
4 days ago
FX Empire
5 days ago